Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | FCER2 | P06734 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682420 | 1.00 | OPRD1 (0.51) | OPRD1OPRM1OPRK1CTSBREN | |
| SCHEMBL722883 | 1.00 | OPRD1 (0.51) | OPRD1OPRM1OPRK1CTSBREN | |
| SCHEMBL1682423 | 1.00 | OPRD1 (0.51) | OPRD1OPRM1OPRK1CTSBREN | |
| SCHEMBL2369018 | 0.94 | OPRD1 (0.53) | OPRD1OPRM1OPRK1CTSB | |
| SCHEMBL12295398 | 0.92 | OPRD1 (0.54) | OPRD1OPRM1OPRK1CTSBREN | |
| SCHEMBL29250280 | 0.92 | OPRD1 (0.52) | OPRD1OPRM1OPRK1CTSBMME | |
| SCHEMBL12808287 | 0.91 | REN (0.55) | OPRD1OPRM1OPRK1CTSBREN | |
| SCHEMBL7259831 | 0.91 | REN (0.55) | OPRD1OPRM1OPRK1CTSBREN | |
| SCHEMBL2369892 | 0.91 | OPRM1 (0.53) | OPRD1OPRM1OPRK1CTSBREN | |
| SCHEMBL7773529 | 0.90 | OPRD1 (0.51) | OPRD1OPRM1OPRK1CTSBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10406111-B2 | Gold/lanthanide nanoparticle conjugates and uses thereof | COLORADO SCHOOL OF MINES (US) | 2019-09-10 | — | — | US | disclosed |
| US-9382346-B2 | Gold nanoparticle conjugates and uses thereof | COLORADO SCHOOL OF MINES (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160017065-A1 | Gold Nanoparticle Conjugates and Uses Thereof | COLORADO SCHOOL OF MINES | 2016-01-21 | — | — | US | disclosed |
| US-9175015-B2 | Gold nanoparticle conjugates and uses thereof | COLORADO SCHOOL OF MINES (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150306256-A1 | Lanthanide Nanoparticle Conjugates and Uses Thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2015-10-29 | — | — | US | disclosed |
| US-20150258034-A1 | GOLD/LANTHANIDE NANOPARTICLE CONJUGATES AND USES THEREOF | COLORADO SCHOOL OF MINES | 2015-09-17 | — | — | US | disclosed |
| US-20150250902-A1 | pH-RESPONSIVE GADOLINIUM NANOPARTICLE CONJUGATES AND USES THEREOF | COLORADO SCHOOL OF MINES (US) | 2015-09-10 | — | — | US | disclosed |
| US-8968705-B2 | Gold/lanthanide nanoparticle conjugates and uses thereof | COLORADO SCHOOL OF MINES (US) | 2015-03-03 | — | — | US | disclosed |
| US-8916135-B2 | Lanthanide nanoparticle conjugates and uses thereof | COLORADO SCHOOL OF MINES (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140141089-A1 | Nanoparticles, Compositions Thereof, and Methods of Use, and Methods of Making the Same | COLORADO SCHOOL OF MINES (US) | 2014-05-22 | — | — | US | disclosed |
| US-20120082728-A1 | MULTIFUNCTIONAL STEALTH NANOPARTICULES FOR BIOMEDICAL USE | UNIVERSITE DE STRASBOURG (FR) | 2012-04-05 | — | — | US | disclosed |
| US-20120052006-A1 | GOLD/LANTHANIDE NANOPARTICLE CONJUGATES AND USES THEREOF | COLORADO SCHOOL OF MINES (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2389199-A2 | MULTIFUNCTIONAL STEALTH NANOPARTICLES FOR BIOMEDICAL USE | THE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010096464-A1 | GOLD/LANTHANIDE NANOPARTICLE CONJUGATES AND USES THEREOF | BOYES STEPHEN G (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010084157-A2 | MULTIFUNCTIONAL STEALTH NANOPARTICLES FOR BIOMEDICAL USE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-07-29 | — | — | WO | disclosed |
| EP-2210616-A1 | Multifunctional stealth nanoparticles for biomedical use | Centre National de la Recherche Scientifique (FR) | 2010-07-28 | — | — | EP | disclosed |
| US-20090060839-A1 | Gold Nanoparticle Conjugates and Uses Thereof | COLORADO SCHOOL OF MINES | 2009-03-05 | — | — | US | disclosed |
| US-20090060840-A1 | Lanthanide Nanoparticle Conjugates and Uses Thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2009-03-05 | — | — | US | disclosed |
| WO-2009026540-A1 | LANTHANIDE NANOPARTICLE CONJUGATES AND USES THEREOF | COLORADO SCHOOL OF MINES (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306256-A1 | Lanthanide Nanoparticle Conjugates and Uses Thereof | SSB, CD47, SLC6A13 | OPRD1 4653/4885OPRM1 4710/4885OPRK1 4673/4885 |
| US-20090060840-A1 | Lanthanide Nanoparticle Conjugates and Uses Thereof | SSB, CD47, SLC6A13 | OPRD1 4653/4885OPRM1 4710/4885OPRK1 4673/4885 |
| US-20120052006-A1 | GOLD/LANTHANIDE NANOPARTICLE CONJUGATES AND USES THEREOF | SSB, LGALS9, LGALS3 | OPRD1 4640/4885OPRM1 4702/4885OPRK1 4654/4885 |
| US-20140141089-A1 | Nanoparticles, Compositions Thereof, and Methods of Use, and Methods of Making the Same | NPC1L1, LIPA, NPC1 | OPRD1 2681/4885OPRM1 2083/4885OPRK1 1493/4885 |
| US-20150258034-A1 | GOLD/LANTHANIDE NANOPARTICLE CONJUGATES AND USES THEREOF | SSB, LGALS9, LGALS3 | OPRD1 4640/4885OPRM1 4702/4885OPRK1 4654/4885 |
| US-10406111-B2 | Gold/lanthanide nanoparticle conjugates and uses thereof | SSB, LGALS9, LGALS3 | OPRD1 4640/4885OPRM1 4702/4885OPRK1 4654/4885 |
| US-20150250902-A1 | pH-RESPONSIVE GADOLINIUM NANOPARTICLE CONJUGATES AND USES THEREOF | GOLGA3, GDI1, CA13 | OPRD1 4845/4885OPRM1 4721/4885OPRK1 4850/4885 |
| US-20160017065-A1 | Gold Nanoparticle Conjugates and Uses Thereof | CD47, SELP, SELPLG | OPRD1 3853/4885OPRM1 2738/4885OPRK1 3151/4885 |
| US-20120082728-A1 | MULTIFUNCTIONAL STEALTH NANOPARTICULES FOR BIOMEDICAL USE | EPHA2, CD47, MSN | OPRD1 2782/4885OPRM1 985/4885OPRK1 1692/4885 |
| US-20090060839-A1 | Gold Nanoparticle Conjugates and Uses Thereof | CD47, SELP, SELPLG | OPRD1 3853/4885OPRM1 2738/4885OPRK1 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.